Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.36 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.36 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.36 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 7/20 | 0.31 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.31 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26513247 | 1.00 | GNAI3 (0.36) | GNAI3GNAO1GNAI1SPHK1CNR2 | |
| SCHEMBL20833075 | 0.89 | GNAI3 (0.42) | GNAI3GNAO1GNAI1SPHK1CNR2 | |
| SCHEMBL23745297 | 0.89 | GNAI3 (0.42) | GNAI3GNAO1GNAI1SPHK1CNR2 | |
| SCHEMBL24429447 | 0.85 | GNAI3 (0.38) | GNAI3GNAO1GNAI1SPHK1 | |
| SCHEMBL23745437 | 0.75 | SMPD1 (0.34) | GNAO1SMPD1FDPS | |
| SCHEMBL14863742 | 0.72 | CYP1A2 (0.33) | CNR2FDPSCNR1 | |
| SCHEMBL24435761 | 0.72 | GNAO1 (0.46) | GNAI3GNAO1GNAI1 | |
| SCHEMBL18609539 | 0.72 | GNAO1 (0.46) | GNAI3GNAO1GNAI1 | |
| SCHEMBL21180109 | 0.72 | GNAO1 (0.46) | GNAI3GNAO1GNAI1 | |
| SCHEMBL11680394 | 0.72 | CYP1A2 (0.43) | CES2LPAR1LPAR3CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322792-A1 | CDK9 INHIBITORS | BAERENKRAFT THERAPEUTICS, LLC | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322792-A1 | CDK9 INHIBITORS | CDK9, CDK19, CDK3 | GNAI3 1172/4885GNAO1 2017/4885GNAI1 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.